# Magnet Biomedicine

> Magnet Biomedicine is a Boston biotechnology company developing molecular glue inhibitors through its TrueGlue platform. It pairs disease targets with selected presenter proteins to seek oral treatments for immune disorders and cancer, and has an oncology discovery and licensing collaboration with Eli Lilly.

- **Founded:** 2019
- **Headquarters:** Boston, United States
- **Founders:** Stuart Schreiber (Scientific co-founder and advisor), Michael Rosbash (Scientific co-founder and advisor), Benjamin F. Cravatt (Scientific co-founder and advisor), Richa Saxena (Scientific co-founder and advisor), David A. Spiegel (Scientific co-founder and advisor)
- **Products:** TrueGlue discovery platform, Molecular glue inhibitor pipeline
- **Notable:** Announced a $50 million Series A and emerged from stealth in September 2023., Signed an oncology collaboration and license agreement with Lilly in February 2025., Publicly lists ST2 and TL1A programs at lead optimization in its current pipeline.

## Products & services

- **TrueGlue discovery platform** — Proprietary discovery platform combining chemical libraries, screening, human biology and target/presenter selection to identify cooperative molecular glue interactions.
- **Molecular glue inhibitor pipeline** — Investigational small molecules designed for presenter-dependent inhibition; the current public pipeline lists ST2 for COPD and asthma and TL1A for multiple indications at lead optimization, with additional discovery-stage immunology and partnered oncology programs.

## Achievements

- Announced a $50 million Series A and emerged from stealth in September 2023.
- Signed an oncology collaboration and license agreement with Lilly in February 2025.
- Publicly lists ST2 and TL1A programs at lead optimization in its current pipeline.

## Latest updates

- **2026-01** — Appointed Nick Vlahakis as chief medical officer to oversee clinical development and medical strategy.
- **2025-11** — Appointed Bharat Reddy as chief business officer.
- **2025-02** — Announced the Lilly oncology collaboration and license agreement.

## Links

- Website: https://magnetbio.com/
- LinkedIn: https://www.linkedin.com/company/magnet-biomedicine/
- Twitter/X: https://x.com/MagnetBiomed

---

Profile page: https://yespress.io/magnet-biomedicine
Published by YesPress — https://yespress.io
Last updated: 2026-10-04